A multicentre trial of Zostrum (5 percent idoxuridine in dimethyl sulphoxide) in herpes zoster.

Abstract

Forty-six patients with herpes zoster were randomised into two groups treated with DMSO alone and 5 percent IDU in DMSO, provided that treatment started within 48 hours of the appearance of a rash. In the IDU group the interval before pain improved was significantly shorter than in the control DMSO group, and significantly fewer new vesicles developed at the three day follow up in the active group compared with the control group. These findings are in agreement with previously published work and confirm the usefulness of Zostrum (5 percent IDU in DMSO) in the treatment of herpes zoster.

• Authors: W J Burton, P W Gould, M W Hursthouse, P J Sears, D A Larnder, H C Stringer, B C Turnbull
• Journal: The New Zealand medical journal (N Z Med J) Vol. 94 Issue 696 Pg. 384-6 (Nov 25 1981) ISSN: 0028-8446 [Print] New Zealand
• PMID: 6459547 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Analgesics
• Idoxuridine
• Dimethyl Sulfoxide

Topics

• Administration, Topical
• Analgesics (therapeutic use)
• Clinical Trials as Topic
• Dimethyl Sulfoxide (adverse effects, therapeutic use)
• Drug Eruptions (etiology)
• Herpes Zoster (drug therapy)
• Humans
• Idoxuridine (adverse effects, therapeutic use)
• Pain (drug therapy)
• Random Allocation